Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81
Document › Details

Boehringer Ingelheim. (8/16/13). "Press Release: Boehringer Ingelheim Takes a Further Step to Establish Animal Health Business in Asia. Ground-breaking Ceremony for Leading Veterinary Manufacturing Plant in Taizhou/China – Investment of 58 Million Euro".

Region Region Taizhou, Jiangsu
  Country China
Organisations Organisation Boehringer Ingelheim veterinary vaccine plant joint venture, Taizhou, China
  Organisation 2 Taizhou China Medical City (Taizhou China Medicine High-Tech Development Zone)
Products Product animal vaccine
  Product 2 animal health
Index term Index term China Medical City–Boehringer: animal vaccine, 201308– collab joint venture for €58m manufacturing plant at China Medical City in Taizhou
Person Person Hasenmaier, Joachim (Boehringer 201210– Managing Director responsible for Consumer Healthcare + Animal Health)

> Ground-breaking ceremony for leading veterinary manufacturing plant in Taizhou/China

> Investment of 58 million Euro

> 200 job opportunities expected

Today, the research driven pharmaceutical company Boehringer Ingelheim, in partnership with Taizhou China Medical City in Jiangsu Province, China, held the ground-breaking ceremony for a veterinary vaccine manufacturing plant at the China Medical City (Taizhou China Medicine High-Tech Development Zone). The joint venture, with investment totaling 58 million Euro, will become a leading manufacturer of veterinary vaccines in Asia upon its completion. The facility is expected to complete construction in June 2015 and to create about 200 job opportunities.

"China is one of the most important Animal Health markets in the world. With the start of this project, we are fulfilling our commitment to providing the entire value chain of our vaccine business in China," said Dr Joachim Hasenmaier, Member of the Board of Managing Directors and responsible for Animal Health: "Taizhou China Medical City, with its favourable geographic location, sound investment environment and well qualified employees, among many other advantages, proved to be an ideal partner for Boehringer Ingelheim. The project underlines our commitment of continued investment in China."

With nearly 60 years of experience in the Animal Health sector, Boehringer Ingelheim is a market leading company and the largest vaccine supplier for swine worldwide. Through this joint-venture, Boehringer Ingelheim is set to introduce leading Animal Health technology in China and to expedite the sector's development in the country. The joint venture will become a leading force for the country's animal husbandry sector, providing scientific, innovative and high-quality solutions in the area of Animal Health. The manufacturing plant will mainly produce vaccines for swine and poultry diseases.

Lu Chunyun, Standing Committee member of Taizhou municipal government and president of China Medical City, said: "Boehringer Ingelheim is a leading player in the world's Animal Health sector, particularly in swine vaccines. China Medical City is the country's only national-level medical high-tech development park. This co-operation is set to create synergy and a win-win situation."

"Boehringer Ingelheim's vision is to become a reliable partner of choice for China's animal breeders and to contribute to food safety in China," said Dr Hasenmaier. "The Animal Health business together with our other strategic pillars - Prescription Medicines, Consumer Healthcare, Biopharmaceuticals and Operations - will continue to bring more health to China."

In 2012, Boehringer Ingelheim China's Animal Health business was ranked among the top three in multinational pharmaceutical companies in China. The success was driven particularly by the growth of the animal vaccine business. The core products, including Ingelvac Circoflex® (which helps to protect swine against Porcine Circovirus Disease), have achieved remarkable market recognition and success. The company also set up its Asian Veterinary Research and Development Center (AVRDC) in Shanghai Zhangjiang High-tech Park early last year.

Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

Social responsibility is a central element of Boehringer Ingelheim's culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavours.

In 2012, Boehringer Ingelheim achieved net sales of about 14.7 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.

Media contact

Boehringer Ingelheim
Matthias Kagerbauer
Binger Strasse 173
55216 Ingelheim am Rhein
Phone +49/6132/77 2356
Fax +49/6132/77 6601

Record changed: 2019-06-09


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80

» top